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www.embomolmed.org EMBOT cell receptor (TCR) down-modulation after antigen presentation is a funda-
mental process that regulates TCR signal transduction. Current understanding of
this process is that intrinsic TCR/CD28 signal transduction leads to TCR down-
modulation. Here, we show that the interaction between programmed cell death
1 ligand 1 (PD-L1) on dendritic cells (DCs) and programmed death 1 (PD-1) on CD8
T cells contributes to ligand-induced TCR down-modulation. We provide evidence
that this occurs via Casitas B-lymphoma (Cbl)-b E3 ubiquitin ligase up-regulation
in CD8 T cells. Interference with PD-L1/PD-1 signalling markedly inhibits TCR
down-modulation leading to hyper-activated, proliferative CD8 T cells as
assessed in vitro and in vivo in an arthritis model. PD-L1 silencing accelerates
anti-tumour immune responses and strongly potentiates DC anti-tumour
capacities, when combined with mitogen-activated kinase (MAPK) modulators
that promote DC activation.INTRODUCTION
The immune system must protect the organism against
infectious diseases and cancer without provoking autoimmu-
nity. T lymphocytes play a key role in the induction of protective
and long-lasting immunity, but, if uncontrolled, can cause
autoreactive disease. For this reason, T cell activation is
regulated at multiple levels, particularly during antigen
presentation. Understanding these mechanisms is essential
for designing effective therapies for the treatment of cancer,
infectious diseases and autoimmune disorders. T cells recognize
specific peptides in association with major histocompatibility
complex (MHC) molecules that are expressed on the surface ofInstitute of Medical
ool, Boston, MA, USA
ndon, UK
, University College
, UK
Mol Med 3, 581–592antigen presenting cells (APCs) through binding of their
respective T cell receptor (TCRs). However, MHC-peptide
recognition is not sufficient for full T cell activation, and a
range of co-stimulatory ligand–receptor interactions is also
required that can provide either positive or negative signals. For
instance the CD80–CD28 interaction is stimulatory, while others
such as programmed cell death 1 ligand 1 (PD-L1)–programmed
death 1 (PD-1) association are inhibitory. The relative
contribution of co-stimulatory/co-inhibitory signals determines
the activation state of T cells, leading to T cell proliferation and
acquisition of effector activities or differentiation into anergic or
regulatory T cells. Thus, the overall integration of positive and
negative signals during co-stimulation provides a checkpoint at
which T cell responses are modulated (Nurieva et al, 2006).
PD-L1 is a member of the B7 family of co-stimulatory/
inhibitory molecules, which is expressed in a wide range of cell
types, including T cells and dendritic cells (DCs; Latchman et al,
2004; Sharpe et al, 2007). PD-1 is transiently up-regulated in
activated T cells during antigen presentation, and its ligation to
PD-L1 recruits src homology 2 domain-containing tyrosine
phosphatases 1 and 2 (SHP 1 and 2) to its intracellular switch
motif. SHPs dephosphorylate effector molecules associated with
the TCR leading to termination of TCR signal transduction
(Chemnitz et al, 2004; Sheppard et al, 2004). 2011 EMBO Molecular Medicine 581
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process of T cell activation at the level of antigen presentation.
TCRs are removed from the T cell surface shortly after
activation, limiting signal transduction and avoiding excessive
responses (Holst et al, 2008; Naramura et al, 2002; San Jose et al,
2000; Schonrich et al, 1991; Shamim et al, 2007). The current
view of ligand-induced TCR down-modulation is that intrinsic
TCR signalling following antigen recognition is sufficient for
TCR down-modulation. However, the exact mechanism by
which this occurs is still under extensive research. Ligand-
induced TCR down-modulation is a complex, multi-mechanistic
process (Lauritsen et al, 1998). It is well established that ligand-
engaged TCR complexes are quickly internalized (Cai et al,
1997; Dietrich et al, 1998; Huppa et al, 2010; Lauritsen et al,
1998; Valitutti et al, 1995). Afterwards, other TCR complexes
including non-engaged ones, are down-regulated following
signal transduction from the triggered TCRs (San Jose et al,
2000). Nevertheless, up-regulation of E3 ubiquitin ligases of the
Casitas B-lymphoma (Cbl) family in T cells contributes to ligand-
induced TCR down-modulation as demonstrated by studies with
Cbl knock-out (KO) mice (Naramura et al, 2002; Shamim et al,
2007). Cbl KO T cells have reduced TCR down-modulation
following antigen presentation, leading to sustained signalling
and hyper-activation (Chiang et al, 2000; Naramura et al, 2002;
Shamim et al, 2007). Interestingly, to date, no additional
extrinsic signals provided by DCs in the immunological synapse,
which are critical for ligand-induced TCR down-modulation,
have been identified.
Counteracting negative signals transmitted to effector T cells
is a promising approach to achieve therapeutic efficacy for
cancer and infectious diseases. Thus, the disruption of PD-L1/
PD-1 signalling pathway, mainly by systemic administration of
blocking antibodies, is receiving increasing interest in immu-
notherapy (Curran et al, 2010; Hirano et al, 2005; Hobo et al,
2010; Zhou et al, 2010). In addition, abrogation of Cbl ubiquitin
ligases in effector T cells significantly enhances their anti-
tumour/anti-viral activities (Bachmaier et al, 2000; Chiang et al,
2000; Naramura et al, 2002; Paolino et al, 2011), making them
attractive therapeutic targets.RESULTS
PD-L1 silencing in DCs inhibits CD8 TCR down-modulation
In this study, we investigated the consequences and therapeutic
outcomes of silencing the co-stimulatory ligand PD-L1 in DCs
during antigen presentation to T cells. Thus, we delivered a PD-
L1-specific short hairpin (sh)RNA (termed p5) using a reported
lentiviral platform (Arce et al, 2011). Transduction of bone
marrow derived DCs (BM-DCs) resulted in the specific silencing
of PD-L1 surface expression with no down-regulation of other
classical DC maturation markers (Fig 1 of Supporting Informa-
tion).
To test the effects of PD-L1 silencing on MHC class I and II
antigen presentation, we co-delivered the shRNA p5with IiOVA,
a well-defined model antigen containing both MHC class I and
class II epitopes (Fig 1A; Arce et al, 2011; Escors et al, 2008). 2011 EMBO Molecular MedicineThus, BM-DCs were transduced with control lentivectors
expressing GFP alone, IiOVA-GFP or IiOVA-p5-GFP. Inclusion
of the shRNA did not alter gene expression from the lentivector
(Fig 1A). BM-DCs transduced with IiOVA-GFP or IiOVA-p5-GFP
activated proliferation of OVA-specific CD4 and CD8 T cells
purified from transgenic OT-II and OT-I mouse strains,
respectively (results not shown). However, while approxi-
mately 40% of CD8 T cells clustered around IiOVA-expressing
DCs after 16 h of culture as assessed bymicroscopy, around 90%
of CD8 T cells clustered around BM-DCs expressing IiOVA-p5
(Fig 1B). By comparison, no differences were observed for DC-
CD4 OT-II cell association, which was around 10% (results not
shown). Therefore, in agreement with other studies (Fife et al,
2009), these results suggested that the DC-CD8 T cell association
was enhanced when PD-L1 was silenced.
To investigate why increased DC-T cell clustering was
observed upon down-regulation of PD-L1, we examined several
potential factors. Interestingly, we found that TCR down-
modulation was significantly inhibited when antigen was
presented in the absence of PD-L1 (Fig 1C and D). Equivalent
results were obtained by surface CD3 staining, the TCR
component mediating signal transduction (Fig 1E and F), and
by staining with OVA-specific class I pentamer (results not
shown). Surface levels of the T cell lineage marker Thy1.2
remained unchanged, confirming the specificity of the TCR
down-modulation (Fig 1E). It is worth noting that TCR down-
modulation reached a maximum on day 3–4, and TCR levels
gradually recovered afterwards (Fig 2 of Supporting Informa-
tion). PD-L1 silencing in DCs significantly delayed TCR down-
modulation but did not completely abrogate it (Fig 2 of
Supporting Information). Persistent TCR signal transduction
was demonstrated by intracellular detection of phosphorylated
extracellular signal-regulated kinase (ERK) in TCRhigh CD8þ T
cells (results not shown).
To confirm that a reduction in DC PD-L1 co-stimulation also
reduced TCR down-modulation on activated T cells in vivo, we
immunized Thy1.1 mice with BM-DCs transduced with the
different lentivectors. Then, congenic Thy1.2 OT-I CD8þ T cells
were adoptively transferred the following day and analysed
7 days later. OVA-specific OT-I cells primed in vivo by DCs with
silenced PD-L1 down-regulated TCR expression to a lesser
extent than T cells primed in the presence of PD-L1 (Fig 2).
Collectively, our results demonstrate that DC-derived PD-L1
signalling contributes to ligand-induced TCR down-modulation
after antigen presentation.
PD-L1 silencing in DCs blocks expression of Cbl E3 ubiquitin
ligases in CD8R T cells
Recent evidence demonstrates that expression of Cbl E3
ubiquitin ligases significantly contributes to ligand-induced
TCR down-modulation and limits TCR signal transduction
(Bachmaier et al, 2000; Chiang et al, 2000; Naramura et al,
2002). Cbl KO T cells exhibit a reduced TCR down-modulation
after antigen presentation, exactly to the same extent as
observed in our experiments (Fig 1; Shamim et al, 2007).
Therefore, we tested whether PD-L1 silencing in antigen-
presenting DCs inhibited up-regulation of the two major CblEMBO Mol Med 3, 581–592 www.embomolmed.org
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Figure 1. PD-L1 silencing in antigen
presenting DCs inhibits TCR down-modulation
in CD8R T cells.
A. Lentivector co-delivery platform of IiOVA
with shRNA-p5 (top). IiOVA expression
(immunoblot, lower left) and GFP expression
(graph, right).
B. Association between lentivector transduced
DCs and antigen specific OT-I cells as
indicated. Associated DC-T cells were
quantified by microscopy.
C. Surface expression of transgenic OVA TCR
chains in OT-I cells co-cultured for 4 days
with DCs transduced with the indicated
lentivectors (top). Transgenic OT-I cells are
Vb5.1.5.2high and Va2.1high (circles), the their
percentages shown within the gate.
D. As in (C), but plotting transgenic
OVA-specific TCR surface expression in OT-I
CD8þ T cells co-cultured with the indicated
transduced DCs (bottom), as a bar graph
with error bars (standard deviations).
, highly significant differences.
E. As in (C), with CD3 surface expression in
Thy1.2-gated T cells. Percentages refer to
CD3high T cells within the upper gate,
delimited with a horizontal dotted line.
Thy1.2 remains unchanged.
F. Bar graph as in (E) plotting results from four
independent experiments. Each of the
experiments is represented as a differently
shaded pair of bars. , significant differences.
Figure 2. Vaccination with a lentivector co-
delivering antigen and a PD-L1-specific shRNA
expands antigen-specific TCRhigh CD8R T cells.
A. Flow cytometry of OVA-specific transgenic TCR
(Va2.1 chain) surface expression in transferred
Thy1.2þ CD8þ T cells in mice vaccinated with
DCs transduced with the indicated lentivectors
on top of the graph. Percentages of high Va2.1
OT-I cells are shown within the graphs.
B. As in (A), but in the form of a histogram
comparing vaccinations with transduced
DCs, including the GFP-DC vaccination
control. Very low numbers of Thy1.2þ cells
were found in GFP-DC vaccinated mice due
to lack of proliferation. Lentivectors used for
DC transductions are shown within the
legend. Numbers refer to Va2.1 mean
fluorescent intensities, and the percentage
to Va2.1-positive OT-I cells, as defined by
those cells within the 95% isotype gate
(horizontal dotted line). The horizontal
dotted line delimits the gate in which 95% of
isotype-stained CD8þ T cells are excluded. I,
Isotype staining control.
C. OVA-specific TCR surface expression as in (B)
in OT-I adoptively transferred into mice
vaccinated with DCs transduced with the
indicated lentivectors (bottom). , indicate
very significant differences.
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584proteins, c-Cbl and Cbl-b, in CD8þ T cells (Fig 3A and B). Our
data show that, while antigen presentation by IiOVA-DCs
strongly up-regulated both Cbl proteins, PD-L1 silencing in
IiOVA-p5-DCs did not result in significant expression of Cbl-b or,
to a lesser extent, c-Cbl (Fig 3B). We found that lack of Cbl-b
expression rather than c-Cbl was consistent with the inhibition
of CD3 internalization (Fig 3C and D).
To confirm that PD-L1/PD-1 co-stimulation was a regulator of
TCR down-modulation and also exclude off-target shRNA-
mediated mechanisms, we repeated our DC-T cell co-cultures in
the presence of well-described PD-L1 or PD-1 blocking
antibodies. Blockade of either the ligand or receptor reprodu-
cibly replicated our findings using PD-L1 silencing in DCs,
including significant inhibition of TCR down-modulation and
Cbl-b expression (Fig 3E and F and data not shown). In fact, CD3
internalization and Cbl-b expression were reduced in a dose-Figure 3. Interference with PD-L1/PD-1 signalling inhibits TCR down-modulat
A. Intracellular expression of Cbl-b and c-Cbl in OT-I cells co-cultured with lentiv
legend within the histograms. Numbers indicate mean fluorescent intensities
B. Same as (A), as a scatter plot representing the fold-change in Cbl mean fluoresc
experiments are plotted and analysed with the Mann–Whitney U-test. , sign
C. Cbl-b and surface CD3 expression in OT-I cells co-cultured with lentivector-tra
cells are shown, as well as populations with different Cbl levels (arrows).
D. Same as in (C), but detecting c-Cbl.
E. Surface CD3 and Thy1.2 expression in OT-I cells co-cultured with DCs expres
blocking antibodies (top of each graph). Percentages of CD3high T cells are in
F. As in (E) but intracellular Cbl-b expression, represented as a histogram and gati
out of two independent experiments. Mean fluorescent intensities are shown
 2011 EMBO Molecular Medicinedependent manner (data not shown). A nearly complete
abrogation of CD3 internalization was achieved with the highest
concentration of PD-1 blocking antibody, while surface levels of
Thy1.2 remained unchanged (Fig 3E). Collectively, these data
demonstrate that the PD-L1/PD-1 interaction contributes to
ligand-induced TCR down-modulation and that it depends on
PD-1 expression in T cells after activation in our experimental
system.
To further demonstrate the requirement for PD-1 expression
in T cells, we silenced PD-1 in human T cells by delivering
shRNAs using lentiviral vectors. We chose human cells due to
their susceptibility to transduction in the absence of activation.
Thus, PD-1-specific shRNAs and GFP were co-delivered under
the control of the U6 and phosphoglycerate kinase (PGK)
promoters. To overcome the necessity of specific antigen
presentation, we stimulated human CD4þ T cells withion by blocking Cbl-b up-regulation.
ector-transduced DCs. Lentivectors used for transduction are indicated in the
. I, isotype control.
ent intenisty compared to T cells co-cultured with GFP-DCs. Four independent
ificant differences.
nsduced DCs as indicated on top of the density plots. Percentages of CD3high T
sing IiOVA, in the presence of the indicated concentrations of PD-L1 or PD-1
dicated within each density plot.
ng in Thy1.2þ T cells. Histograms in this figure came from a single experiment
. I, isotype control.
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gen, following a published protocol (Horgan et al, 1990).
Accordingly, CD3 surface down-modulation was significantly
inhibited following PD-1 silencing in stimulated GFPþ CD4þ T
cells, although not completely abrogated (results not shown).
We reproduced these results with shRNAs targeted to three
different PD-1 regions.
PD-L1 silencing in DCs leads to hyperactivated
pro-inflammatory TCRhigh CD8R T cells
To investigate whether PD-L1-induced dysregulation of TCR
internalization altered the function of primed T cells, we initiallyFigure 4. PD-L1 silencing in antigen presenting DCs results in hyperactivated
A. The gating of OT-I cells according to Vb5.1.5.2 expression is shown. T cell po
proliferation analyses by CFSE dilution in TCRhigh OT-I co-cultured with lentiv
B. Flow cytometry analyses of CFSE dilution in Vb5.1.5.2high OT-I cells co-cultured
the graph). The horizontal line within the graph delimits CFSE high T cells (9
C. Same as B, showing the mean percentages of CFSE high OT-I cells with error b
(bottom). , highly significant differences.
D. IFN-g and IL-17 expression in OT-I cells co-cultured with lentivector-transduce
gates.
E. As in (D), plotting mean percentages and error bars from three experiments,
F. Knee inflammation after intra-articular challenge with OVA in groups of five
lentivector-transduced DCs (legends within the graph) and intravenously tran
significant differences.
G. Percentage of OVA-specific endogenous CD8þ T cells in draining lymph nodes sta
lentivectors used for DC transduction (bottom). Means and error bars from th
H. CD8þ responses by IFN-g ELISPOT on day 7 after vaccination with lentivecto
www.embomolmed.org EMBO Mol Med 3, 581–592compared proliferation in T cells incubated with BM-DCs
transduced with IiOVA or IiOVA-p5 lentivectors. As expected,
an inverse correlation between surface expression of TCR chains
and proliferation was observed (Fig 4A–C). In contrast, T cells
stimulated in the presence of reduced PD-L1 signalling
proliferated more extensively in vitro, even though they had
significantly increased TCR levels (Fig 4B and C). These T cells
produced increased levels of IFN-g and IL-17, suggesting an
enhanced pro-inflammatory phenotype (Fig 4D and E). Detec-
tion of annexin V in DC-T cell co-cultures indicated that
apoptosis was not increased in T cells primed in the absence of
PD-L1 (data not shown). Therefore, these data suggested thatpro-inflammatory TCRhigh CD8R T cells.
pulations were separated into high, medium and low surface expression for
ector-transduced DCs.
for 4 days with DCs transduced with the indicated lentivectors (shown within
5% of unstimulated OT-I).
ars are plotted (three experiments) according to Vb5.1.5.2 surface expression
d DCs (top). Percentage and mean fluorescent intensities are shown within the
including IL-2 expression. , significant differences.
mice. One day before challenge, OT-I cells were co-cultured with
sferred. Means are plotted with error bars (standard deviations). , very
ined with class I OVA-pentamers, on day 7 after vaccination with the indicated
ree experiments are plotted.
r-transduced DCs (bottom).
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586activation of CD8þ T cells without PD-L1 co-stimulation results
in the expansion of a hyperactivated population of cells. This
phenotype was very similar to that of hyperactivated TCRhigh
T cells from Cbl KO mice (Chiang et al, 2000; Naramura et al,
2002), which spontaneously develop lethal autoimmune
disorders (Naramura et al, 2002). Therefore, we tested whether
T cells primed in the absence of PD-L1 co-stimulation could
cause immune pathology in a well-established inflammatory
arthritis model using OVA as a surrogate autoantigen (Arce et al,
2011; Fig 4F). Transfer of T cells primed by DCs transduced with
IiOVA-p5 resulted in severe knee inflammation after intra-
articular challenge with OVA compared to mice that had
received T cells primed with DCs expressing IiOVA, which
inducedmuch less severe inflammation. Therefore, these results
show that T cell priming without PD-L1 co-stimulation leads to
the development of hyperactivated T cells, which cause
significant immune pathology in vivo if directed towards an
autoantigen (Fig 4F).
Our conclusions were further reinforced by studying the
endogenous CD8þ T cell expansion after subcutaneous
vaccination with lentivector-modified DCs. Effector CD8þ T
cell expansion was significantly increased 7 days after
immunization when PD-L1 was silenced in DCs as observed
by pentamer-staining in draining lymph nodes (Fig 4G) and IFN-
g ELISPOT in splenocytes (Fig 4H). Numbers of pentamer-
positive CD8þ T cells after vaccination with PD-L1-silenced
IiOVA-DCs remained higher than in non-silenced vaccination
controls up to 3 weeks after vaccination, with high pentamer 2011 EMBO Molecular Medicinefluorescent intensities that probably reflect high TCR surface
levels (Fig 5). These results suggested an accelerated or
uncontrolled CD8þ T cell activation/expansion in agreement
with our in vitro studies using OT-I cells.
PD-L1 silencing in DCs accelerates anti-tumour immune
responses
Our observation that lentivector delivery of antigen with PD-L1
silencing induced potent inflammatory T cells suggested that
these T cells could be a useful means of enhancing immunity in
the context of anti-tumour therapy. Thus, we tested the
therapeutic efficacy in an EG7 mouse lymphoma model (EL4
cells expressing OVA as a surrogate tumour antigen). Sub-
cutaneous administration of EG7 cells results in aggressive solid
lymphomas, which can be effectively treated by vaccination
with IiOVA-expressing DCs (Escors et al, 2008). DCs were
transduced with lentivectors expressing GFP alone, IiOVA-GFP
or IiOVA-p5-GFP and were injected subcutaneously when
tumours were detectable (on day 4 or 5; Fig 6A). The therapeutic
immunization with as few as 105 IiOVA-p5-GFP transduced DCs
significantly reduced tumour growth compared to non-silenced
controls (Fig 6B). As a consequence, a significant increase in
lifespan of tumour-bearing mice was observed (Fig 6C).
Surprisingly, overall survival after 1 month was similar when
compared to non-silenced DC counterparts (Fig 6D). Thus, our
data strongly suggested that PD-L1 silencing inhibited tumour
growth and prolonged survival, but did not increase cure rates.
All surviving tumour-free mice pooled from three independentFigure 5. PD-L1 silencing in DCs accelerates
expansion of endogenous antigen-specific
CD8R T cells. As in Fig 4G, flow cytometry
analyses of endogenous OVA-specific CD8þ T
cells expanded after vaccination with the
indicated transduced DCs (top of the graphs).
T cells from draining inguinal lymph nodes were
stained with a class I-specific OVA pentamer,
and percentages of pentamer-specific OT-I cells,
with their corresponding mean fluorescent
intensities are shown in each graph. Analyses
were performed 1 week after vaccination (top
row, indicated on the right of the graphs),
2 weeks (middle row) and 3 weeks (bottom row).
Vaccination groups consisted of between 3 and
5 mice. Plots correspond to individual mice.
EMBO Mol Med 3, 581–592 www.embomolmed.org
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Figure 6. PD-L1 silencing in antigen presenting DCs
accelerates anti-tumour activities.
A. Tumour progression in mice vaccinated with lenti-
vector-transduced DCs. Data from individual mice
are represented as independent lines.
B. Same as (A) but on day 10 (peak of tumour size). Each
mouse represented as a dot. Means from each group
are indicated within the graph with horizontal lines.
Comparisons were performed with the Mann–
Whitney U-test. , highly significant differences.
C. Time of death from tumour bearing mice. Vaccina-
tion groups indicated on the bottom. Means from
each group are indicated within the graph with
horizontal lines. Comparisons were performed with
the Mann–Whitney U-test. , significant differences.
D. As in (A), representing the Kaplan–Meier survival plot.
Statistical significance was tested with the log-rank
test. Ns, no significant differences.
E. Kaplan–Meier survival plot-in surviving tumour-free
mice from experiments as in (D), re-challenged with
EG7 lymphoma cells. A control group with naive mice
was used.experiments were resistant to re-challenge with EG7 cells
demonstrating effective recall responses (Fig 6E).
PD-L1 silencing potentiates the adjuvant capacities of
molecular DC activators
To test whether anti-tumour immunity could be further
improved, we combined PD-L1 silencing with the expression
of selected DC molecular activators (Arce et al, 2011; Escors
et al, 2008). PD-L1 shRNA p5 was co-delivered with IiOVA and a
constitutive activator of mitogen-activated kinase (MAPK) p38
(MKK6EE) or the ERK inhibitor MEK1 DNES AA (Fig 7A). We
chose these MAPK modulators because we have previously
demonstrated that p38 activation and ERK inhibition using these
modulators increase expression of co-stimulatory and adhesion
molecules in DCs such as CD80, CD40 and ICAM I (Arce et al,
2011; Escors et al, 2008). Vaccination with a low dose of
transduced DCs (104/mouse) showed a synergistic increase in
CD8þ responses by IFN-g ELISPOT when p5 was co-delivered
with MAPK modulators (Fig 7A). Immunization with as few as
104 PD-L1-silenced DCs activated with MAPK modulators
resulted in effective control of tumour growth compared to
mice receiving DC with IiOVA alone (Fig 7B). The combination
of ERK inhibition with PD-L1 silencing was particularly effectivewww.embomolmed.org EMBO Mol Med 3, 581–592in reducing tumour growth (Fig 7B). Interestingly, PD-L1
silencing with either ERK inhibition or p38 activation sig-
nificantly increased tumour-free survival (Fig 7C). This suggests
that whilst PD-L1 inhibition can generate a T-cell response
superior at controlling tumour growth, additional co-stimula-
tory signals (via DC activation) are required to optimize T-cell
functionality for efficient tumour killing (Fig 7C). These data
demonstrate that in the absence of PD-L1 silencing, as few as 104
activated DCs are sufficient to prime potent CD8þ T cell
responses, which can control tumour growth. We further show
that by improving the potency of DCs, in conjunction with
removal of PD-L1-based regulation, we can generate signifi-
cantly enhanced T cell immunity, capable of controlling tumour
growth in a therapeutic setting.DISCUSSION
We have provided evidence that PD-L1 in antigen presenting
DCs contributes to ligand-induced TCR down-modulation.
Ligand-induced TCR down-modulation is a complicated process
in which more than one mechanism is involved (Lauritsen et al,
1998). Firstly, serially ligand-engaged TCRs internalize quickly 2011 EMBO Molecular Medicine 587
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Figure 7. PD-L1 silencing increases adjuvant capacities of selected DC activators.
A. Top, lentivector structure used for the experiments. Bottom, graphs represent CD8þ T cell responses by IFN-g ELISPOT-In splenocytes 7 days after vaccination
with the indicated lentivector-transduced DCs. MKK6, the p38 activator MKK6EE mutant; MEK AA, the ERK inhibitor MEK1 DNES AA.
B. Tumour size on day 8 (peak of tumour size) in mice vaccinated with the indicated lentivector-transduced DCs. Group combinations from two different
experiments have been combined in a single graph, and are separated with a vertical dotted line. Means from each group are indicated within the graph with
horizontal lines. Statistical comparisons were performed using the Kruskall–Wallis non-parametric test. , significant differences.
C. As in (B), but representing the Kaplan–Meier survival plots. Vaccination groups are indicated within the plots. Statistical significance was tested with the log-
rank test. , significant differences; , highly significant differences.
588(from seconds to hours) after ligand–MHC binding (Huppa et al,
2010; Valitutti et al, 1995). Secondly, non-engaged TCR
complexes can also be down-regulated following signal
transduction from previously engaged (and endocytosed) TCR
complexes (San Jose et al, 2000). It is still under debate whether
TCR down-modulation is caused by internalization followed by
degradation or by preventing TCR recycling back to the
membrane (Dietrich et al, 1998; San Jose et al, 2000; Valitutti
et al, 1995). Interestingly, we have observed that TCR down-
modulation progressively continues up to 3 days after initial
antigen presentation by DCs. Subsequently, TCR surface levels
recover again. This TCR down-modulation may be caused by
either direct internalization or just a shift in recycling towards
intracellular retention of TCR complexes (San Jose et al, 2000;
Valitutti et al, 1995). Our results implicate PD-L1/PD-1 co-
stimulation in the second, slower phase and they are in
agreement with the following working model for regulation of T
cell activation during antigen presentation by DCs (Fig 8):
Firstly, antigen recognition (with additional co-stimulatory
interactions) leads to TCR signal transduction. Following T cell
activation, PD-1 is exposed to the T cell surface where it engages
with PD-L1 on the surface of the APC. PD-1 signal transduction
recruits SHP phosphatases and, importantly, leads to Cbl-b 2011 EMBO Molecular Medicineexpression by a yet undefined pathway. Cbl-b ubiquitinates and
inactivates key TCR signal transduction mediators, while
removing TCRs from the T cell surface. Whether this removal
is triggered by active internalization or a change in the dynamics
of TCR recycling is yet unclear. Our data supports PD-1 as an
early brake that fine-tunes T cell activation during antigen
presentation after TCR signal transduction. In any case, our
model can provide an explanation for results reported in several
unrelated studies. Firstly, TCR/CD28 signal transduction per se
is not required for full ligand-induced TCR down-modulation, as
observed in Cbl-b KO CD8þ T cells (Shamim et al, 2007).
Secondly, PD-1 blocking antibodies inhibit Cbl-b transcriptional
up-regulation, amongst other negative regulators of T cell
activation as shown by polymerase chain reaction (after reverse
transcription) (RT-PCR; Nurieva et al, 2006). Thirdly, human T
cells activated in vitro with anti-CD3/anti-CD28 antibodies
maintain high surface TCR levels when compared to antigen
presentation by APCs (Yang et al, 2010). And fourthly, old
human CD8þ T cells, which maintain low surface TCR levels,
significantly increase their surface expression after in vitro
activation with anti-CD3/anti-CD28 antibodies only in the
presence of PD-L1 blocking antibodies (Mirza et al, 2010). This
last observation would implicate PD-L1/PD-1 homotypic T cellEMBO Mol Med 3, 581–592 www.embomolmed.org
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Figure 8. PD-1-dependent early brake model of T cell
activation.
A. Antigen presenting cell (APC; top) presents antigen in
the context of MHC. T cell TCR recognizes the antigen
(together with CD80–CD28 binding, not shown for
simplification purposes) and leads to activating
signal transduction. PD-1 surface expression is up-
regulated.
B. PD-1 on the surface engages with PD-L1 on the APC’s
surface, leading to recruitment of SHP phosphatases
and up-regulating Cbl-b expression.
C. SHP and Cbl-b de-phosphorylate and inactivate by
ubiquitination, respectively, key components of the
TCR signal transduction machinery.
D. Cbl-b either triggers TCR down-modulation, or shifts
the recycling equilibrium towards retention of TCR
complexes.interactions (T cell–T cell) either in trans or in cis as suggested
by others (Fooksman et al, 2010). The interpretation of all these
results is, therefore, straightforward if PD-L1/PD-1 binding
contributes to ligand-induced TCR down-modulation through
Cbl-b expression.
Unexpectedly, we did not observe significant ligand-induced
TCR down-modulation after 3–4 days co-culture of OVA-specific
CD4þ T cells with IiOVA-expressing BM-DCs, whether PD-L1
was silenced or not. Accordingly, we were unable to test in the
mouse model if PD-L1/PD-1 co-stimulation was involved in
CD4þ TCR down-modulation. It is worth noting that unlike
CD8þ T cells, only a minor proportion of OVA-specific OT-II T
cells strongly associated to IiOVA-expressing DCs. This is in
agreement with other reports inwhich naive CD4þ T cells detach
quickly from APCs, but they get fully activated later by multiple,
short-lived contacts (Celli et al, 2005). However, it is likely that
PD-L1/PD-1 interactionmay also be involved in CD4 TCR down-
modulation as we did observe inhibition of TCR down-
modulation in PD-1-silenced human CD4 T cells, but in the
context of superantigen stimulation.
PD-L1/PD-1 interaction is receiving an increasing interest as a
therapeutic target. While most of the studies use systemic
administration of blocking antibodies, a minor proportion have
silenced B7 inhibitory molecules in DCs (Breton et al, 2009;
Hobo et al, 2010). In any case, therapeutic outcomes vary
considerably and are quite dependent on the specific experi-
mental system. In many instances, combination with other
strategies has to be applied to achieve effective therapy (Breton
et al, 2009; Curran et al, 2010; Hobo et al, 2010; Pilon-Thomas
et al, 2010). In our experimental system, PD-L1 silencing in DCs
alone did not improve overall cure rates compared to non-
silenced DCs. PD-L1 silencing had to be combined with DC
molecular activators to achieve increased therapeutic activities.
Curiously, this phenomenon is observed in many otherwww.embomolmed.org EMBO Mol Med 3, 581–592published studies and may account for the relative lack of
efficacy of PD-L1/PD-1 blocking antibodies unless they are
given in combination therapies. Thus, the anti-tumour efficacy
of PD-L1/PD-1 blocking antibodies is enhanced by lentivector
vaccination (Sierro et al, 2011; Zhou et al, 2010). In these two
last reports, an increased recruitment of tumour infiltrating
CD8þ T cells was observed after systemic administration of PD-
L1/PD-1 antibodies. In agreement with this, we also observed a
tendency to increased intra-tumour CD8þ T cell numbers in
mice vaccinated with IiOVA-expressing PD-L1-silenced DCs.
However, we could not demonstrate significance in relative
numbers or TCR surface levels compared to vaccination with
non-silenced DCs. In contrast to systemic administration of
blocking antibodies, PD-L1 silencing in our experimental model
is taking place in a limited number of DCs. Secondly, we could
not differentiate a specific recruitment of effector CD8þ T cells
from just simply an overall increase in CD8þ T cell numbers
(Figs 4 and 5). However, in light to previous reports, it is likely
that also in our case, there is an enhanced, active intra-tumoural
recruitment of CD8þ T cells.
Summarizing, our results demonstrate that PD-L1 silencing in
DCs may speed-up T cell expansion and cytokine responses
(which is important for tumour immunotherapy) but other
factors also contribute to the effectiveness of the immune
response, for instance the functionality of activated T-cells
which is a direct consequence of a range of co-stimulatory
signals during antigen presentation. Further co-stimulation
could enhance the expression of cytotoxic molecules in effector
CD8þ T cells such as granzyme B and perforin, which could be
responsible for the observed increase in therapeutic activity.
Our model highlights the contribution of PD-L1/PD-1 co-
stimulation to ligand-induced TCR down-modulation during
‘physiological’ antigen presentation by DCs. This is a very
complex process that is regulated at multiple levels, and there 2011 EMBO Molecular Medicine 589
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The paper explained
PROBLEM:
Our study addresses a fundamental immunological mechanism
for the control of T cell activation during antigen presentation,
TCR down-modulation. This process limits TCR signal trans-
duction and prevents T cell hyperactivation after antigen-
presentation by dendritic cells. Current understanding of this
process is that intrinsic TCR/CD28 signal transduction leads to
TCR internalization. However, to date, no additional extrinsic
signals have been identified which contribute to TCR down-
modulation.
RESULTS:
We show here that binding of PD-L1 on dendritic cells to PD-1 on
T cells is implicated in ligand-induced TCR down-modulation, by
promoting Cbl-b E3 ubiquitin ligase expression. This finding
expands the role of PD-L1 in immune regulation to a critical step
in T cell activation.
We have further analysed the consequences of preventing TCR
down-modulation, in vitro and in vivo in two very different
disease models; antigen-specific inflammatory arthritis and a
T cell-derived lymphoma. By combining PD-L1 silencing with
modulators of selected signalling pathways (MAPKs) in dendritic
cells, we have increased their anti-tumour activities, obtaining
therapeutic effects with doses 100-to-1000-fold lower than
those currently used in experimental cancer models and in
human clinical trials.
IMPACT:
Our study will be of interest to a broad range of basic researchers
in cell biology, immunology, rheumatology as well as clinicians. Our
findings will be of particular importance for clinical application in
autoimmune disorders and cancer, as they highlight TCR trafficking
and its interference as a potential key therapeutic target.
590are other pathways that inhibit effector T cell activities without
modifying TCR levels (Barber et al, 2006; Choi & Schwartz,
2007; Wherry, 2011). Defining the mechanism by which PD-1
engagement leads to Cbl-b up-regulation and modulates TCR
levels is a key question in T cell physiology and a potential target
for therapeutic intervention.MATERIALS AND METHODS
Cells and mice
293T, EG7 cells and BM-DCs were grown as described (Escors et al,
2008). Approval for the animal studies was obtained from the
University College London Animal Ethics Committee. The following
mouse strains were used: C57BL/6 mice, OT-I and OT-II mice. The last
two strains express a transgenic TCR specific for MHC- class I and class
II OVA epitopes, respectively. DC-T cell co-cultures were performed as
described (Arce et al, 2011). T cells were added to DCs 3 days after
transduction at a ratio of 10:1, and co-cultured for a minimum of
2 days and a maximum of 1 week. When indicated, isotype antibody
control, purified anti-mouse PD-L1 clone MIH5 or anti-mouse PD-1
antibody clone RMP1-14 were added to DCs after lentivector
transduction, at the concentrations indicated in the text. These last
two antibodies are well-characterized blocking antibodies (Freeman
et al, 2000; Kanai et al, 2003). Intracellular cytokine detection by flow
cytometry was performed as described (Arce et al, 2011). Immuno-
blots using HA-specific antibodies were performed as described (Escors
et al, 2008).
Plasmids, lentivector production, titration and cell
transduction
Dual lentivectors co-expressing MAPK modulators along with GFP or
HA-tagged IiOVA were used (Arce et al, 2011; Escors et al, 2008). The 2011 EMBO Molecular Medicinesequence of the PD-L1-specific shRNA used in the present experiments
(designated p5) was 50-CTCGAGAAGGTATATTGCTGTTGACAGTGAGC-
GAGCGTTGAAGATACAAGCTCAATAGTGAAGCCACAGATGTATTGAGCTTG-
TATCTTCAACGCCTGCCTACTGCCTCGGAATTC-30 . The sequences of the
PD-1-specific shRNAs are: PD-1A 50-GTGCTAAACTGGTACCGCATTT-
CAAGAGAATGCGGTACCAGTTTAGCATTTTTTACGCGT0-30 , PD-1B 50-
GCCACCATTGTCTTTCCTAGTTCAAGAGACTAGGAAAGACAATGGTGGTTTTT-
TACGCGT-30 and PD-1C 50-GCCAACACATCGGAGAGCTTTTCAAGA-
GAAAGCTCTCCGATGTGTTGGTTTTTTACGCGT-30 . For cloning and
expression of PD-1-specific shRNAs, a lentivector was constructed
based on pDUAL containing a U6 promoter replacing the SFFV
promoter, and a PGK promoter replacing the ubiquitin promoter.
Lentivectors were produced and titrated as described (Kochan et al,
2008; Selden et al, 2007). BMDCs were transduced using previously
described protocols (Escors et al, 2008). Human CD4 T cells were
transduced as described (Frecha et al, 2008).
Cell staining and flow cytometry
Surface and intracellular staining were performed as described
previously (Escors et al, 2008). The following anti-mouse antibodies
were purchased from eBioscience, with isotype controls: Biotinylated
antibodies specific for Thy1.2, CD80, CD40, PD-L1, PD-L2, phycoery-
thrin (PE)-conjugated anti CD25, anti-CD8, anti-ICAM I, anti-MHC I,
anti-MHC II, anti-CD3, PE-Cy7-conjugated anti-CD4, allophycocyanin
(APC)-conjugated anti-Foxp3, anti-IFN-g, anti-CD3, fluorescein iso-
thiocyanate (FITC)-conjugated anti-IL17, anti IL-2 and anti-PD-1 clone
J43. The following antibodies were purchased from BD Bioscience
Pharmingen: Biotinylated anti-mouse Vb 5.1 5.2 TCR, Alexa Fluor 647-
conjugated anti-mouse phosphoERK 1/2. FITC- and PE-conjugated
anti-Va2 TCR were purchased from Caltag laboratories. Cbl-b goat
polyclonal IgG and Alexa fluor 647-conjugated c-Cbl antibodies
were purchased from Santa Cruz Biotechnology. Alexa Fluor 488-
conjugated donkey anti-goat IgG was purchased from Invitrogen.EMBO Mol Med 3, 581–592 www.embomolmed.org
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(BD Biosciences). Pentamer staining was performed as described
(Arce et al, 2011).
Vaccination, T cell responses and tumour experiments
All vaccination experiments were repeated independently at least
three times, using groups of five mice, as described (Breckpot et al,
2010; Escors et al, 2008; Goold et al, 2011). IFN-g ELISPOTs were
performed as described (Escors et al, 2008).
Therapeutic tumour experiments were performed as described before,
using 10 mice per vaccination groups (Escors et al, 2008). Lentivector-
transduced DCs at the indicated doses were injected subcutaneously
when tumours were detectable (on day 4 or 5). Tumour growth was
monitored daily and mice were sacrificed when tumour surface was
higher than 140–150mm2.
T cell purification, CFSE labelling, adoptive transfer and
antigen-induced arthritis
Untouched CD4þ T or CD8þ T cells were purified from mouse spleens
using the Dynal Mouse CD4 or CD8 Negative Isolation Kit (Invitrogen).
T cells were labelled with CFSE as described (Arce et al, 2011). Purified
OT-I cells were adoptively transferred intravenously (between 106 and
108 cells/mouse) into groups of five mice, when indicated. After
transfer, antigen-induced arthritis was triggered by intra-articular
injection of 100mg of purified OVA (Sigma) in 10ml of PBS. Knee
inflammation was monitored daily. The experiment was repeated
twice.
Statistical analysis
ELISPOT data was analysed as described (Arce et al, 2011; Escors et al,
2008). Normally, a minimum of three independent experiments was
performed with five mice per group. For tumour experiments, 10 mice
per group per experiment were used. Mean fluorescence intensities
from surface or intracellular staining were analysed as described (Arce
et al, 2011; Escors et al, 2008). Survival data from tumour
experiments was compared using the log-rank test as described
before (Escors et al, 2008). CD3 surface expression levels, tumour size
between groups and lifespan of tumour-bearing mice were compared
using the non-parametric Mann–Whitney U-test or Kruskall–Wallis
test for multicomparisons.Author contributions
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